Browsing by Author "Simsek, Yasemin"
Now showing 1 - 20 of 44
- Results Per Page
- Sort Options
Conference Object Age Matters: Distinct Disability Patterns in Multiple Sclerosis Patients Initiating Therapy After the Age of 50(Sage Publications Ltd, 2025) Zengin, Ela; Caliskan, Can; Simsek, Yasemin; Unal, Gozde Deniz; Ozakbas, SerkanConference Object Association Between Vascular Risk Factors and Cognitive Impairment in Multiple Sclerosis: a Cross-Sectional Study(Sage Publications Ltd, 2024) Ozakbas, Serkan; Aslan, Taha; Zengin, Ela; Kara, Irem; Simsek, Yasemin; Kahraman, TurhanConference Object Can the Age of the First Symptom for Neuromyelitis Optica be Used to Predict Cognitive Impairment(Sage Publications Ltd, 2024) Unal, Gozde Deniz; Alizada, Said; Kara, Irem; Simsek, Yasemin; Ozakbas, SerkanConference Object Can the age of the first symptom for neuromyelitis optica be used to predict cognitive impairment?(Sage Publications Ltd, 2024) Unal, Gozde Deniz; Alizada, Said; Kara, Irem; Simsek, Yasemin; Ozakbas, Serkan[No abstract available]Conference Object Clinical Characteristics and Disease Progression in Multiple Sclerosis: A Comparison of Late Middle-Age Onset vs Late Adulthood Onset(Sage Publications Ltd, 2025) Ozakbas, Serkan; Simsek, Yasemin; Caliskan, Can; Ozdogar, Asiye TubaConference Object Comparative Analysis of Comorbidities in Neuromyelitis Optica Spectrum Disorders and Multiple Sclerosis: Insights Into Disease Pathogenesis and Management(Sage Publications Ltd, 2024) Ozakbas, Serkan; Kaya, Ergi; Simsek, Yasemin; Abasiyanik, ZuhalConference Object Determinants of Fatigue in People With Multiple Sclerosis: An Investigative Analysis(Sage Publications Ltd, 2024) Ozdogar, Asiye Tuba; Alizada, Said; Simsek, Yasemin; Ozakbas, SerkanConference Object Evaluating the Impact of MS Medications on Pregnancy Outcomes: A Retrospective Cohort Study(Sage Publications Ltd, 2024) Kaya, Ergi; Simsek, Yasemin; Ozcelik, Sinem; Caliskan, Can; Ozakbas, SerkanConference Object Evaluation of Disability in Individuals with Multiple Sclerosis Using Clinician-Rated and Patient-Reported Measures: A Cross-Sectional and Retrospective Study(Sage Publications Ltd, 2025) Caliskan, Can; Simsek, Yasemin; Samadzade, Ulvi; Ozakbas, SerkanConference Object Evaluation of Hepatitis B Virus Status in Patients Treated With Rituximab: A Retrospective Cohort Study(Sage Publications Ltd, 2025) Samadzade, Ulvi; Simsek, Yasemin; Ozakbas, SerkanConference Object Examining Classical Cerebro-Spinal Fluid Biomarkers in Primary Progressive Multiple Sclerosis:implications for Prognosis(Sage Publications Ltd, 2024) Yapici, Nurbanu; Kaya, Ergi; Simsek, Yasemin; Ozakbas, SerkanConference Object Exploring Familial Multiple Sclerosis: Insights From a Cohort Analysis(Sage Publications Ltd, 2024) Ozakbas, Serkan; Simsek, Yasemin; Caliskan, Can; Ozcelik, SinemConference Object Exploring the Impact: An Analysis of Cladribine Treatment in Multiple Sclerosis Management(Sage Publications Ltd, 2024) Ozakbas, Serkan; Kaya, Ergi; Simsek, Yasemin; Ozdogar, Asiye Tuba[No Abstract Available]Article Familial Multiple Sclerosis Is Associated With Accelerated Progression to Secondary Progressive Phase: A Retrospective Single-Center Cohort Study(Springer Heidelberg, 2025) Ozakbas, Serkan; Alizada, Said; Caliskan, Can; Simsek, Yasemin; Zengin, Ela SimayBackground Familial multiple sclerosis (MS), defined by the occurrence of MS in one or more relatives, is thought to represent a genetically influenced subtype of the disease. Objective To compare clinical progression, cerebrospinal fluid (CSF) parameters, and treatment responses between familial and sporadic MS patients. Methods We conducted a retrospective analysis of 1,035 patients diagnosed with MS according to the 2017 McDonald criteria (523 familial, 512 sporadic). Demographic variables, MS subtypes, expanded disability status scale (EDSS) scores, CSF oligoclonal band (OCB) status, IgG index, and treatment regimens were evaluated. Statistical tests included t tests, chi-square, and multivariable regression. Results Familial MS patients showed a higher incidence of secondary progressive MS (10.9%) compared to sporadic cases (7.0%, p = 0.030). Disease duration was significantly longer in familial MS (14.5 vs. 12.3 years, p < 0.01) though time to diagnosis did not differ. OCB positivity rates were comparable, but the IgG index was significantly elevated in familial MS (p < 0.01). Treatment responses did not differ between groups. Conclusion Familial MS is associated with more rapid disease progression and enhanced humoral immune activation, suggesting a distinct phenotype. These findings support the need for genetic and immunologic investigations to guide personalized treatment strategies.Conference Object Familial Multiple Sclerosis: Unveiling Disease Progression and Clinical Correlates(Sage Publications Ltd, 2024) Simsek, Yasemin; Alizada, Said; Caliskan, Can; Ozakbas, SerkanConference Object Familial Patterns and Clinical Correlates of Neuromyelitis Optica: Insights From a Cohort Study(Sage Publications Ltd, 2024) Ozakbas, Serkan; Caliskan, Can; Simsek, Yasemin; Zengin, ElaConference Object A Generation Apart: Long-Term Outcomes of People with Multiple Sclerosis Diagnosed in the 1990s vs 2010s(Sage Publications Ltd, 2025) Ozakbas, Serkan; Samadzade, Ulvi; Simsek, Yasemin; Caliskan, CanConference Object Impact of Aquaporin-4 Serostatus on Disease Activity and Disability in Nmosd: A Five-Year Comparative Study(Sage Publications Ltd, 2025) Kaya, Ergi; Simsek, Yasemin; Ozakbas, SerkanConference Object Impact of Body Weight on Five-Year Progression in Multiple Sclerosis: a Longitudinal Study(Sage Publications Ltd, 2024) Unal, Gozde Deniz; Abasiyanik, Zuhal; Simsek, Yasemin; Zengin, Ela; Ozakbas, SerkanConference Object Impact of Early Treatment Modification on Long-Term Outcomes in Treatment-Naive Multiple Sclerosis Patients: Adverse Reactions and Compliance Challenges(Sage Publications Ltd, 2024) Samadzade, Ulvi; Baba, Cavid; Simsek, Yasemin; Unal, Gozde Deniz; Kara, Irem; Ertekin, Ozge; Ozakbas, Serkan
- «
- 1 (current)
- 2
- 3
- »